News

Olympia Pharmaceuticals | 503B Outsourcer | 503A Compounding Pharmacy

Market 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

Olympia Pharmaceuticals, operating as both a 503B FDA-registered outsourcing facility and a 503A compounding pharmacy, has expanded its product directory to include a wide array of injectable peptides and wellness compounds. The company markets these formulations for weight management, longevity, and sexual health, offering nationwide shipping and office-use solutions to healthcare providers. This expansion reflects the growing consumer demand for compounded alternatives to branded weight loss drugs and peptide-based therapies.

Related peptides

BPC-157TB-500CJC-1295GLP-1 receptor agonistsGLP-1N-peptideLongevityPeptide TBPC-157 / TB-500 BlendGLP-1 receptor agonistGLP-1R
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.